Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Lenvima (10 MG Daily Dose)
(United States) [Available] ,Lenvima (12 MG Daily Dose)
(United States) [Available] ,Lenvima (14 MG Daily Dose)
(United States) [Available] ,Lenvima (18 MG Daily Dose)
(United States) [Available] ,Lenvima
(United States) [Available]Synonyms :
relatlimab
Class :
Class: antineoplastic agents Subclass: VEGF inhibitor
Brand Name :
Lenvima (10 MG Daily Dose)
(United States) [Available] ,Lenvima (12 MG Daily Dose)
(United States) [Available] ,Lenvima (14 MG Daily Dose)
(United States) [Available] ,Lenvima (18 MG Daily Dose)
(United States) [Available] ,Lenvima
(United States) [Available]Synonyms :
relatlimab
Class :
Class: antineoplastic agents Subclass: VEGF inhibitor
Dosage Forms & Strengths:   Â
CapsuleÂ
4 mgÂ
10 mgÂ
20
mg
Orally 
4 times a day
It is given in combination with 200 mg of intravenous pembrolizumab every 3 weeks
Indicated for patients with differentiated thyroid cancer. It may be progressive, locally recurrent, or metastatic, radioactive iodine-refractory differentiated thyroid cancer.
24 mg orally each day (two 10 mg capsules plus one 4 mg capsule)
Combination therapy with everolimus:
lenvatinib- 18 mg (one 10 mg capsule plus two 4 mg capsules) orally each day, with everolimus- 5 mg orally each day
Combination therapy with pembrolizumab:
lenvatinib- 20 mg orally each day, with pembrolizumab 200 mg intravenously for 3 weeks or 400 mg every 6 weeks
For <60 kg: 8 mg orally each day
For ≥60 kg: 12 mg orally each day
It is not safe to administer lenvatinib in the pediatric population
Refer to the adult dosing
QTc interval increases on taking amisulpride and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking aripiprazole and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking artemether and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking atomoxetine and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking desflurane and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking deutetrabenazine and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking donepezil and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking doxepin and lenvatinib together. Avoid or take an alternate drug.
QTc interval increases on taking efavirenz and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking encorafenib and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking entrectinib and lenvatinib together. Avoid or take an alternate drug
the level or effect of fedratinib is increased by lenvatinib
QTc interval increases on taking fexinidazole and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking gadobenate and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking gilteritinib and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking glasdegib and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking hydroxyzine and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking inotuzumab and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking isoflurane and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking itraconazole and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking lefamulin and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking lithium and lenvatinib together. Avoid or take an alternate drug
the effect of lonafarnib is increased by lenvatinib by altering intestinal or hepatic CYP3A4 enzyme metabolism. Avoid or take an alternate drug.
the impact of pacritinib is decreased by lenvatinib by altering intestinal or hepatic CYP3A4 enzyme metabolism. Avoid or take an alternate medicine.
it increases the toxic levels of lenvatinib. Avoid or take an alternate drug.
QTc interval increases on taking panobinostat and lenvatinib together. Avoid or take an alternate drug.
QTc interval increases on taking pitolisant and lenvatinib together. Avoid or take an alternate drug
QTc interval of one another increases on taking ponesimod and lenvatinib together. Avoid or take an alternate drug
QTc interval increases on taking sevoflurane and lenvatinib together. Avoid or take an alternate drug
the level of effect of sotorasib will decrease by MDR1 P-glycoprotein efflux transporter
the level of impact of tepotinib will increase by MDR1 P-glycoprotein efflux transporter.
QTc interval is increased both by lenvatinib and dabrafenib
QTc interval is increased both by lenvatinib and dasatinib
QTc interval is increased both by lenvatinib and degarelix
QTc interval is increased both by lenvatinib and dichlorphenamide
QTc interval is increased both by lenvatinib and azithromycin
QTc interval is increased both by lenvatinib and dofetilide
QTc interval is increased both by lenvatinib and dolasetron
QTc interval is increased both by lenvatinib and dronedarone
QTc interval is increased both by lenvatinib and droperidol
the level of effect of lenvatinib will increase by MDR1 P-glycoprotein efflux transporter due to elagolix
QTc interval is increased both by lenvatinib and eliglustat
the level of lenvatinib increases due to a decrease in metabolism by eluxadoline
QTc interval is increased both by lenvatinib and eribulin
QTc interval is increased both by lenvatinib and erythromycin base
QTc interval is increased both by lenvatinib and erythromycin ethylsuccinate
QTc interval is increased both by lenvatinib and erythromycin lactobionate
QTc interval is increased both by lenvatinib and erythromycin stearate
QTc interval is increased both by lenvatinib and escitalopram
QTc interval is increased both by lenvatinib and ezogabine
the effect of finerenone is increased by lenvatinib by altering intestinal or hepatic CYP3A4 enzyme metabolism
QTc interval is increased both by lenvatinib and fingolimod
QTc interval is increased both by lenvatinib and flecainide
the level of lenvatinib increases due to a decrease in metabolism by eluxadoline
QTc interval is increased both by lenvatinib and floxuridine
QTc interval is increased both by lenvatinib and fluconazole
QTc interval is increased both by lenvatinib and fluoxetine
QTc interval is increased both by lenvatinib and formoterol
the levels of lenvanitib are increased by fostamatinib or vice-versa
the levels of lenvanitib are increased by fostemsavir or vice-versa
QTc interval is increased both by lenvatinib and gemifloxacin
QTc interval is increased both by lenvatinib and gemtuzumab
The levels of lenvatinib increase by glecaprevir/pibrentasvir or vice-versa
The levels of lenvatinib increase by glecaprevir/pibrentasvir or vice-versa
QTc interval is increased both by lenvatinib and goserelin
QTc interval is increased both by lenvatinib and granisetron
QTc interval is increased both by lenvatinib and haloperidol
QTc interval is increased both by lenvatinib and histrelin
QTc interval is increased both by lenvatinib and ibutilide
QTc interval is increased both by lenvatinib and iloperidone
QTc interval is increased both by lenvatinib and indacaterol
the effect of isavuconazonium sulfate is increased by lenvatinib by altering intestinal or hepatic CYP3A4 enzyme metabolism
the level of impact of lenvatinib will increase by MDR1 P-glycoprotein efflux transporter due to istradefylline
the effect of lemborexant is increased by lenvatinib by altering intestinal or hepatic CYP3A4 enzyme metabolism
the level of letermovir is increased by lenvatinib by decreasing the metabolism
QTc interval is increased both by lenvatinib and leuprolide
QTc interval is increased both by lenvatinib and ofloxacin
QTc interval is increased both by lenvatinib and lopinavir
the effect of lemborexant is increased by lenvatinib by altering intestinal or hepatic CYP2C19 enzyme metabolism
QTc interval is increased both by lenvatinib and methadone
the effect of midazolam is increased by lenvatinib by altering intestinal or hepatic CYP3A4 enzyme metabolism
QTc interval is increased both by lenvatinib and mifepristone
QTc interval is increased both by lenvatinib and moxifloxacin
QTc interval is increased both by lenvatinib and nilotinib
QTc interval is increased both by lenvatinib and ofloxacin
QTc interval is increased both by lenvatinib and ondansetron
QTc interval is increased both by lenvatinib and osilodrosta
QTc interval is increased both by lenvatinib and paliperidone
QTc interval is increased both by lenvatinib and pasireotide
QTc interval is increased both by lenvatinib and pazopanib
QTc interval is increased both by lenvatinib and pentamidine
QTc interval is increased both by lenvatinib and perflutren
QTc interval is increased both by lenvatinib and pimozide
QTc interval is increased both by lenvatinib and posaconazole
QTc interval is increased both by lenvatinib and procainamide
QTc interval is increased both by lenvatinib and propafenone
QTc interval is increased both by lenvatinib and quetiapin
QTc interval is increased both by lenvatinib and quinidine
QTc interval is increased both by lenvatinib and ranolazine
the levels of lenvanitib are increased by regorafenib or vice-versa
QTc interval is increased both by lenvatinib and romidepsin
the levels of lenvanitib are increased by safinamide or vice-versa
QTc interval is increased both by lenvatinib and salmeterol
QTc interval is increased both by lenvatinib and saquinavir
toxicity of Lenvatinib is increased by sodium sulfate/potassium sulfate/magnesium sulfate
toxicity of Lenvatinib is increased by sodium sulfate/potassium sulfate/magnesium sulfate
toxicity of Lenvatinib is increased by sodium sulfate/potassium sulfate/magnesium sulfate
QTc interval is increased both by lenvatinib and sorafenib
QTc interval is increased both by lenvatinib and sotalol
The effect level of lenvatinib will increase by the MDR1 P-glycoprotein efflux transporter due to stiripentol
QTc interval is increased both by lenvatinib and sunitinib
QTc interval is increased both by lenvatinib and telavancin
QTc interval is increased both by lenvatinib and tetrabenazine
QTc interval is increased both by lenvatinib and thioridazine
QTc interval is increased both by lenvatinib and toremifene
QTc interval is increased both by lenvatinib and vandetanib
QTc interval is increased both by lenvatinib and vemurafenib
QTc interval is increased both by lenvatinib and voriconazole
QTc interval is increased both by lenvatinib and ziprasidone
the levels of lenvanitib are increased by acalabrutinib or vice-versa.
QTc intervals are increased both by lenvatinib and albuterol.
QTc intervals are increased both by lenvatinib and alfuzosin.
QTc interval are increased both by lenvatinib and amiodarone.
QTc intervals are increased both by lenvatinib and anagrelide.
the effect of lenvatinib is decreased by apalutamide, thereby increasing elimination.
the effect of lenvatinib is decreased by apalutamide, thereby increasing elimination.
QTc interval is increased both by lenvatinib and arformoterol.
QTc interval is decreased both by lenvatinib and arsenic trioxide
QTc interval is increased both by lenvatinib and asenapine
QTc interval is increased both by lenvatinib and azithromycin
QTc interval is decreased both by lenvatinib and bedaquilin
the level of effect of lenvatinib will increase by MDR1 P-glycoprotein efflux transporter due to berotralstat
QTc interval is increased both by lenvatinib and bosutinib
QTc interval is increased both by lenvatinib and capecitabine
QTc interval is increased both by lenvatinib and ceritinib
QTc interval is increased both by lenvatinib and chloroquine
QTc interval is increased both by lenvatinib and chlorpromazine
QTc interval is increased both by lenvatinib and ciprofloxacin
QTc interval is increased both by lenvatinib and citalopram
QTc interval is increased both by lenvatinib and clarithromycin
QTc interval is increased both by lenvatinib and clozapine
QTc interval is increased both by lenvatinib and crizotinib
It may enhance the effect when combined with tafamidis meglumine
Actions and Spectrum:
Actions:
Spectrum:
Adverse drug reactions:   Â
Frequency defined:   Â
>10% Â
Urinary tract infection (11%)Â
Insomnia (12%)Â
Epistaxis (12%)Â
Alopecia (12%)Â
Dyspepsia (13%)Â
Dizziness (15%)Â
Dry mouth (17%)Â
Dysgeusia (18%)Â
Rash (21%)Â
Peripheral edema (21%)Â
Cough (24%)Â
Oral pain (25%)Â
Constipation (29%)Â
Dysphonia (31%)Â
Abdominal pain (31%)Â
Palmar-plantar erythrodysesthesia (32%)Â
Proteinuria (34%)Â
Vomiting (36%)Â
Headache (38%)Â
Stomatitis (41%)Â
Hypertension, grades 3-4 (44%)Â
Nausea (47%)Â
Weight decreased (51%)Â
Decreased appetite (54%)Â
Arthralgia/myalgia (62%)Â
Fatigue (67%)Â
Diarrhea (67%)Â
Hypertension (73%)Â
1-10%Â
Decreased platelet count (2%)Â
Nausea, grades 3-4 (2%)Â
Creatinine increased (3%)Â
Lipase increased (4%)Â
ALT increased (4%)Â
AST increased (5%)Â
Hypokalemia (6%)Â
Hyperkeratosis (7%)Â
Decreased appetite, grades 3-4 (7%)Â
Hypocalcemia (9%)Â
Prolonged QT interval (9%)Â
Dehydration (9%)Â
Diarrhea, grades 3-4 (9%)Â
Hypotension (9%)Â
Dental infections (10%)Â
Â
Contraindication/Caution:
Contraindications:
Pregnancy Â
Animal studies reveal data about the mechanism of action; wherein lenvatinib can cause harm to an ingrowing fetus.Â
Breastfeeding warnings:   Â
It is advised to discontinue lactation during and after the treatment up to 1 week later the last dose. The drug distribution in breast milk is unknown but shows some adverse reactions.Â
Pregnancy Categories:Â
Pharmacology:
lenvatinib is a multi-targeted tyrosine kinase inhibitor that is used to treat various types of cancer. Its pharmacology involves the inhibition of multiple receptor tyrosine kinases that are involved in tumor growth, angiogenesis, and metastasis. Some of the receptors that lenvatinib targets include the fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and epidermal growth factor receptor (EGFR).
Pharmacodynamics:
The pharmacodynamics of lenvatinib include inhibition of angiogenesis, which is the formation of new blood vessels, and tumor growth. Lenvatinib inhibits the signaling pathways of various growth factors and receptors that are responsible for tumor cell proliferation, survival, and migration. By blocking these pathways, lenvatinib can prevent the growth and spread of cancer cells.
Pharmacokinetics:
The pharmacokinetics of lenvatinib are as follows
Absorption
Peak plasma is achieved 1-4 hours after oral administration
Distribution
Protein-bound is 98-99%
Metabolism
The drug is metabolized by CYP3A enzymes and aldehyde oxidase
Elimination
The half-life is 28 hours
The drug is excreted 64% in feces and 25% in urine (10 days later the single dose)
Administration:
lenvatinib is an oral medication that is usually taken once a day, at the same time each day, with or without food. The dosage of lenvatinib varies depending on the type of cancer being treated, the patient’s weight, and other medical conditions.
It is important to take lenvatinib exactly as prescribed by the healthcare provider. Patients should not alter the dose or stop taking the medication without first consulting their doctor. If a patient misses a dose of lenvatinib, they should take it as soon as they remember. If it is within 12 hours of the next dose, the missed dose should be skipped, and the regular dosing schedule should be resumed.
lenvatinib is available as capsules and tablets, and patients should swallow the medication whole with a glass of water without chewing or crushing it. Patients should not consume grapefruit or grapefruit juice while taking lenvatinib, as it can increase the level of the medication in the blood and lead to an increased risk of side effects.
Patient information leaflet
Generic Name: lenvatinib
Pronounced: len-VA-ti-nib
Why do we use lenvatinib?
lenvatinib is used to treat various types of cancer, including:
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
